BRIEF published on 04/15/2025 at 10:05, 8 months 7 days ago IOmx Therapeutics Gains Approval for IOMX-0675 Clinical Trials Immune Response IOmx Therapeutics IOMX-0675 Clinical Trial Approval Solid Tumor Therapy
BRIEF published on 04/15/2025 at 10:05, 8 months 7 days ago IOmx Therapeutics obtient l'approbation pour les essais cliniques sur IOMX-0675 Réponse Immunitaire IOmx Therapeutics IOMX-0675 Approbation Des Essais Cliniques Thérapie Des Tumeurs Solides
PRESS RELEASE published on 04/15/2025 at 10:00, 8 months 7 days ago iOmx Therapeutics Receives Regulatory Approval of Clinical Trial Application for IOMX-0675 iOmx Therapeutics receives regulatory approval for clinical trial application of IOMX-0675, a LILRB1/LILRB2 dual-targeting antibody, to reverse immune suppression in solid tumors Regulatory Approval Clinical Trial Application IOmx Therapeutics IOMX-0675 Solid Tumor
BRIEF published on 12/19/2024 at 14:05, 1 year ago IOmx Therapeutics Advances IOMX-0675 with Clinical Trial Application Cancer Treatment Clinical Trial Application IOmx Therapeutics IOMX-0675 Immunosuppressive Receptors
BRIEF published on 12/19/2024 at 14:05, 1 year ago IOmx Therapeutics fait progresser IOMX-0675 avec une application d'essai clinique Traitement Du Cancer Thérapeutique IOmx IOMX-0675 Demande D'essai Clinique Récepteurs Immunosuppresseurs
PRESS RELEASE published on 12/19/2024 at 14:00, 1 year ago iOmx Therapeutics submits Clinical Trial Application for IOMX-0675 iOmx Therapeutics submits Clinical Trial Application for IOMX-0675, a dual-targeting antibody demonstrating strong anti-tumor potential by reprogramming myeloid cells and restoring cytotoxic T cell function Clinical Trial Application IOmx Therapeutics IOMX-0675 Immunosuppressive Receptors Anti-tumor Potential
BRIEF published on 08/22/2024 at 10:05, 1 year 4 months ago IOmx Therapeutics Initiates Phase Ib with OMX-0407 Cancer Therapy Clinical Trial IOmx Therapeutics OMX-0407 Phase Ib
BRIEF published on 08/22/2024 at 10:05, 1 year 4 months ago IOmx Therapeutics lance la phase Ib avec OMX-0407 Essai Clinique Thérapie Contre Le Cancer OMX-0407 Phase Ib Thérapeutique IOmx
PRESS RELEASE published on 08/22/2024 at 10:00, 1 year 4 months ago iOmx Therapeutics Initiates Phase Ib with OMX-0407 iOmx Therapeutics initiates Phase Ib clinical trial with OMX-0407, showing favorable safety profile and anti-tumor activity in solid tumors. Expansion phase opens in kidney cancer and angiosarcoma Solid Tumors Clinical Trial IOmx Therapeutics OMX-0407 Phase Ib
BRIEF published on 06/27/2024 at 10:05, 1 year 5 months ago IOmx Therapeutics Appoints Florian Schmid as New Chief Financial Officer Chief Financial Officer Biopharmaceutical Leadership IOmx Therapeutics Florian Schmid
Published on 12/22/2025 at 15:00, 6 hours 28 minutes ago World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares
Published on 12/22/2025 at 14:40, 6 hours 48 minutes ago Namibia Critical Metals Inc. Receives Proceeds of $1,154,762 from Exercise of Warrants
Published on 12/22/2025 at 14:30, 6 hours 58 minutes ago Prospect Ridge Updates Diamond Drill Program at 100% Owned Camelot Copper-Gold Project in B.C.'S Cariboo Mining District
Published on 12/22/2025 at 14:00, 7 hours 28 minutes ago Rio Grande Resources Completes 2025 Field Program and Advances Drill Targeting at the Winston Gold-Silver Project
Published on 12/22/2025 at 14:00, 7 hours 28 minutes ago PPX Mining Appoints Ernest Mast as President and CEO and Announces Stock Option Grants
Published on 12/22/2025 at 20:16, 1 hour 11 minutes ago EQS-Adhoc: PIERER Mobility AG (to be renamed soon to Bajaj Mobility AG): CEO Gottfried Neumeister confirmed until the end of 2028
Published on 12/22/2025 at 19:31, 1 hour 57 minutes ago EQS-Adhoc: Marley Spoon Group SE: CEO Daniel Raab Re-appointed and Contract to be Extended until June 2029
Published on 12/22/2025 at 19:00, 2 hours 28 minutes ago PATRIMOINE ET COMMERCE: Déclarations des transactions sur actions propres (hors contrat de liquidité) réalisées le 19 décembre 2025
Published on 12/22/2025 at 18:51, 2 hours 36 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 12/22/2025 at 18:33, 2 hours 55 minutes ago ABEO SE RENFORCE ET OBTIENT UNE TRÈS LARGE MAJORITÉ DU CAPITAL DE VOGO AVEC 90,84% DÉTENUS À L’ISSUE DE L’OFFRE RÉOUVERTE
Published on 12/22/2025 at 18:05, 3 hours 23 minutes ago Covivio - Treasury shares transactions between December 15th , 2025 and December 19th, 2025
Published on 12/22/2025 at 18:05, 3 hours 23 minutes ago Covivio - Déclaration des transactions sur actions propres réalisées du 15 décembre au 19 décembre 2025
Published on 12/22/2025 at 17:45, 3 hours 43 minutes ago Déclaration des transactions sur actions propres réalisées du 15 au 19 décembre 2025 dans le cadre du programme de rachat d’actions
Published on 12/22/2025 at 17:35, 3 hours 53 minutes ago DECLARATION HEBDOMADAIRE D'OPERATIONS EFFECTUEES DU 15 AU 19 DECEMBRE 2025
